0001623082-24-000005.txt : 20241101 0001623082-24-000005.hdr.sgml : 20241101 20241101152034 ACCESSION NUMBER: 0001623082-24-000005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241030 FILED AS OF DATE: 20241101 DATE AS OF CHANGE: 20241101 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SALAMON STEVEN A J CENTRAL INDEX KEY: 0001623082 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16133 FILM NUMBER: 241418776 MAIL ADDRESS: STREET 1: 15 WELLESLEY STREET WEST, SUITE 326 CITY: TORONTO STATE: A6 ZIP: M4Y 0G7 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DELCATH SYSTEMS, INC. CENTRAL INDEX KEY: 0000872912 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 061245881 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 566 QUEENSBURY AVENUE CITY: QUEENSBURY STATE: NY ZIP: 12804 BUSINESS PHONE: (518) 743-8892 MAIL ADDRESS: STREET 1: 566 QUEENSBURY AVENUE CITY: QUEENSBURY STATE: NY ZIP: 12804 FORMER COMPANY: FORMER CONFORMED NAME: DELCATH SYSTEMS INC DATE OF NAME CHANGE: 19990607 4 1 primary_doc.xml PRIMARY DOCUMENT X0508 4 2024-10-30 0 0000872912 DELCATH SYSTEMS, INC. DCTH 0001623082 SALAMON STEVEN A J 15 WELLESLEY STREET WEST, SUITE 326 TORONTO A6 M4Y 0G7 ONTARIO, CANADA 1 0 0 0 0 Tranche B warrants to purchase F-4 Preferred Stock 1000 2024-10-30 4 M 0 500 1000 A 2023-03-29 F-4 PREFERRED STOCK 500 0 I By Rosalind Advisors, Inc., the advisor to the Rosalind Funds 8% CONVERTIBLE NOTE 0 2024-10-30 4 H 0 0 0 A CASH 1423333 0 I By Rosalind Advisors, Inc., the advisor to the Rosalind Funds Immediately exercisable The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026. The Issuer announced on October 17, 2024 that it had recorded at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and therefore such Tranche B Warrants expire on November 7, 2024. Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein N/A Delcath repaid the DELCATH SYSTEM - 8% CONVERTIBLE NOTE in full with cash of $1,423,333. Steven Salamon 2024-11-01